BMY.SW stock fell 4.40% after hours to CHF42.54 on 05 Feb 2026 after a sharp volume spike. Trade showed volume 500.00 versus an average of 22.00, a relative volume of 22.73x, suggesting outsized selling interest. The one-line take: after-hours flow has amplified a short-term re-test risk and requires watching support near the year low.
After-hours volume spike: BMY.SW stock price action
BMY.SW stock moved from a previous close of CHF44.50 to CHF42.54 in after-hours trading, a -1.96 CHF change or -4.40%. Reported trading volume was 500.00 versus an average daily volume of 22.00, producing a relative volume of 22.73x. That spike indicates concentrated orders outside open hours and raises the chance of a short-term momentum reversal.
Earnings and fundamentals: BMY.SW stock earnings and metrics
Bristol-Myers Squibb Company (BMY.SW) lists EPS 2.33 and a trailing PE of 18.26. Shares outstanding are 1,662,049,470.00 and reported market cap is CHF70,703,584,454.00. Key cash metrics show free cash flow per share 6.28 and cash per share 6.46. The company reports an earnings announcement timestamp dated 05 Feb 2026, which can amplify after-hours moves.
Valuation snapshot and sector comparison for BMY.SW stock
On valuation, BMY.SW shows a price-to-sales 1.28, price-to-book 4.55, and a debt-to-equity near 3.45, reflecting heavier leverage. Compare that to the Switzerland healthcare sector average PE of 34.55 and typical defensive profiles; BMY.SW trades cheaper on PE but carries higher leverage. Dividend yield stands at about 3.50%, with a payout ratio near 0.84.
Technical view and price targets for BMY.SW stock
Short-term technicals show the share price at the session low and at the year low of CHF42.54, with a year high at CHF44.75. For planning, realistic price targets: conservative CHF37.00, base CHF42.00, bullish CHF48.00. Use tight stops; after-hours volume spikes often foreshadow intraday continuation. Watch support at CHF42.54 and resistance near CHF44.50.
Risks, catalysts and sector context for BMY.SW stock
Primary risks include high leverage, patent and pipeline execution, and macro drug pricing pressure. Catalysts that could stabilise the stock are earnings clarity on 05 Feb 2026 and positive product news. Healthcare sector momentum in Switzerland has a YTD gain of 4.23%, which could help if company news is neutral. Market headlines and macro coverage may move shares; follow market feeds like CNBC Halftime and regional summaries at MarketWatch Latest News.
Meyka grade and forecast for BMY.SW stock
Meyka AI rates BMY.SW with a score out of 100: 68.27 (Grade B) — HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a one-year target of CHF39.34, versus the current CHF42.54, implying a one-year downside of -7.53%. Forecasts are model-based projections and not guarantees. For more details see our platform: Meyka BMY.SW page.
Final Thoughts
Key takeaways for BMY.SW stock: the after-hours drop to CHF42.54 on 05 Feb 2026 accompanied by a 22.73x relative volume signals elevated short-term risk. Financially, EPS 2.33 and a trailing PE 18.26 make the company look cheaper than some peers, but leverage (debt-to-equity 3.45) raises dilution and refinancing concerns. Meyka AI’s forecast model projects CHF39.34 one-year, implying -7.53% from today’s price; alternate scenarios place conservative support at CHF37.00 and a bullish recovery to CHF48.00. Traders should treat the move as a volume-driven re-test candidate and use earnings clarity and intraday volume to confirm bias. These notes are analysis, not investment advice; Meyka AI is an AI-powered market analysis platform and this piece includes model-based projections and a proprietary grade for context.
FAQs
What caused the BMY.SW stock after-hours drop on 05 Feb 2026?
The after-hours drop to CHF42.54 came with a volume surge (500.00 vs avg 22.00). That spike suggests concentrated selling around the earnings window and created a short-term momentum move rather than a broad-market selloff.
Is BMY.SW stock cheap compared with its sector?
Relative to the healthcare sector PE of about 34.55, BMY.SW’s trailing PE of 18.26 looks cheaper. Higher leverage and payout ratio moderate that view, so valuation alone may not signal a buy without earnings clarity.
What short-term price levels should investors watch for BMY.SW stock?
Watch immediate support at the year low CHF42.54 and resistance near the previous close CHF44.50. Conservative downside target CHF37.00 and bullish recovery near CHF48.00 guide risk management.
How reliable is the Meyka AI forecast for BMY.SW stock?
Meyka AI’s forecast model projects CHF39.34 one-year and provides probabilistic guidance. These model-based projections are not guarantees and should be used with fundamental and technical checks.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
What brings you to Meyka?
Pick what interests you most and we will get you started.
I'm here to read news
Find more articles like this one
I'm here to research stocks
Ask our AI about any stock
I'm here to track my Portfolio
Get daily updates and alerts (coming March 2026)